相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Concatenated γ-aminobutyric acid type A receptors revisited: Finding order in chaos
Vivian Wan Yu Liao et al.
JOURNAL OF GENERAL PHYSIOLOGY (2019)
Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes
Jeffrey W. Chen et al.
ANNALS OF PHARMACOTHERAPY (2019)
The pharmacokinetics and the pharmacodynamics of cannabinoids
Catherine J. Lucas et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
Elizabeth A. Thiele et al.
LANCET (2018)
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
Orrin Devinsky et al.
NEUROLOGY (2018)
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome
Orrin Devinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience
Kerrie-Anne Chen et al.
MEDICAL JOURNAL OF AUSTRALIA (2018)
Interactions between cannabidiol and commonly used antiepileptic drugs
Tyler E. Gaston et al.
EPILEPSIA (2017)
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Rongrui Tang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Orrin Devinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors
T. Bakas et al.
PHARMACOLOGICAL RESEARCH (2017)
Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome
Joshua S. Kaplan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Screening of conventional anticonvulsants in a genetic mouse model of epilepsy
Nicole A. Hawkins et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2017)
Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol
Reesha R. Patel et al.
BRAIN (2016)
Efficacy of antiepileptic drugs for the treatment of Dravet syndrome with different genotypes
Xiu-Yu Shi et al.
BRAIN & DEVELOPMENT (2016)
Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex
Evan J. Hess et al.
EPILEPSIA (2016)
Mortality in Dravet syndrome: A review
Sharon Shmuely et al.
EPILEPSY & BEHAVIOR (2016)
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Orrin Devinsky et al.
LANCET NEUROLOGY (2016)
Fine Mapping of a Dravet Syndrome Modifier Locus on Mouse Chromosome 5 and Candidate Gene Analysis by RNA-Seq
Nicole A. Hawkins et al.
PLOS GENETICS (2016)
Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy
Alexandra L. Geffrey et al.
EPILEPSIA (2015)
The Direct Actions of GABA, 2′-Methoxy-6-Methylflavone and General Anaesthetics at β3γ2L GABAA Receptors: Evidence for Receptors with Different Subunit Stoichiometries
Han Chow Chua et al.
PLOS ONE (2015)
Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability
Fabio Arturo Iannotti et al.
ACS CHEMICAL NEUROSCIENCE (2014)
Clobazam and Its Active Metabolite N-desmethylclobazam Display Significantly Greater Affinities for α2- versus α1-GABAA-Receptor Complexes
Henrik Sindal Jensen et al.
PLOS ONE (2014)
Impaired excitability of somatostatin- and parvalbumin-expressing cortical interneurons in a mouse model of Dravet syndrome
Chao Tai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Cannabidiol Is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19
Rongrong Jiang et al.
DRUG METABOLISM AND PHARMACOKINETICS (2013)
Influence of CYP2C19 Polymorphism and Concomitant Antiepileptic Drugs on Serum Clobazam and N-Desmethyl Clobazam Concentrations in Patients With Epilepsy
Yoshiaki Yamamoto et al.
THERAPEUTIC DRUG MONITORING (2013)
GABA(A) Receptor Physiology and Its Relationship to the Mechanism of Action of the 1,5-Benzodiazepine Clobazam
Raman Sankar
CNS DRUGS (2012)
Pharmacokinetic Drug Interactions Between Clobazam and Drugs Metabolized by Cytochrome P450 Isoenzymes
Mark Walzer et al.
PHARMACOTHERAPY (2012)
Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures
Nicholas A. Jones et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2012)
Dravet syndrome: The long-term outcome
Pierre Genton et al.
EPILEPSIA (2011)
Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes
Rongrong Jiang et al.
LIFE SCIENCES (2011)
Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety
Satoshi Yamaori et al.
LIFE SCIENCES (2011)
Molecular basis of severe myoclonic epilepsy in infancy
Kazuhiro Yamakawa
BRAIN & DEVELOPMENT (2009)
Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy
Takayuki Seo et al.
PHARMACOGENOMICS (2008)
The orphan receptor GPR55 is a novel cannabinoid receptor
E. Ryberg et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism
C Giraud et al.
DRUG METABOLISM AND DISPOSITION (2006)
分享论文
